Download PDF
CC BY 4.0 · Rev Bras Ginecol Obstet 2022; 44(03): 319-324
DOI: 10.1055/s-0042-1748463
Febrasgo Position Statement

Genitourinary Syndrome of Menopause

Number 3 - March 2022
Ana Lúcia Ribeiro Valadares 
1   Universidade Estadual de Campinas, Campinas, SP, Brazil
,
Jaime Kulak Junior 
2   Universidade Federal do Paraná, Curitiba, PR, Brazil
,
Lúcia Helena Simões da Costa Paiva 
3   Universidade Estadual de Campinas, Campinas, SP, Brazil
,
Elizabeth Jeha Nasser 
4   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina do ABC, Santo André, SP, Brazil
,
Célia Regina da Silva 
5   Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
,
Eliana Aguiar Petri Nahas 
6   Universidade Estadual Paulista “Júlio de Mesquita Filho”, Botucatu, SP, Brazil
,
Luiz Francisco Cintra Baccaro 
7   Universidade Estadual de Campinas, Campinas, SP, Brazil
,
Márcio Alexandre Hipólito Rodrigues 
8   Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
,
Marco Aurélio Albernaz 
9   Universidade Federal de Goiás, Goiânia, GO, Brazil
,
Maria Celeste Osório Wender 
10   Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
Maria Célia Mendes 
11   Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
,
Rita de Cassia de Maio Dardes 
12   Departamento de Ginecologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
,
Rodolfo Strufaldi 
13   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina do ABC, Santo André, SP, Brazil
,
Rogerio Cesar Bocardo 
14   Faculdade de Medicina de Jundiaí, Jundiaí, SP, Brazil
,
Luciano de Melo Pompei 
15   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina do ABC, Santo André, SP, Brazil
› Author Affiliations
› Further Information
   Permissions and Reprints

Key points

  • Genitourinary syndrome is a complex chronic syndrome with multiple changes in genitourinary tissues in response to menopausal loss of estrogen.

  • Symptoms range from mild to severe and may have effects on genitourinary and sexual function, relationships and quality of life.

  • Treatments can be non-hormonal with lubricants and moisturizers or with vaginal or systemic estrogen therapy.

  • A multidisciplinary approach may be needed when there are complex problems, including sexual dysfunction.

  • The gynecologist is in a unique position to sensitively discuss the symptoms of genitourinary syndrome, advise, educate and treat appropriately, providing long-term follow-up.

The National Specialty Commission on Climateric of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses to this document. The content production is based on scientific studies on a thematic proposal and the findings presented contribute to clinical practice.




Publication History

Article published online:
16 May 2022

© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21 (10) 1063-8
    CrossrefPubMedSearch in Google Scholar
  • 2 Cagnacci A, Xholli A, Sclauzero M, Venier M, Palma F, Gambacciani M. et al. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric 2019; 22 (01) 85-9
    CrossrefPubMedSearch in Google Scholar
  • 3 Nappi RE, de Melo NR, Martino M, Celis-González C, Villaseca P, Röhrich S. et al. Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America. Climacteric 2018; 21 (04) 397-403
    CrossrefPubMedSearch in Google Scholar
  • 4 The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 2020; 27 (09) 976-92
    CrossrefPubMedSearch in Google Scholar
  • 5 Frank SM, Ziegler C, Kokot-Kierepa M, Maamari R, Nappi RE. Vaginal Health: Insights, Views & Attitudes (VIVA) survey – Canadian cohort. Menopause Int 2013; 19 (01) 20-7
    CrossrefPubMedSearch in Google Scholar
  • 6 Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10 (07) 1790-9
    CrossrefPubMedSearch in Google Scholar
  • 7 Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?. Climacteric 2016; 19 (02) 151-61
    CrossrefPubMedSearch in Google Scholar
  • 8 Potter N, Panay N. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. Climacteric 2021; 24 (01) 19-24
    CrossrefPubMedSearch in Google Scholar
  • 9 Dos Santos CC, Uggioni ML, Colonetti T, Colonetti L, Grande AJ, Da Rosa MI. Hyaluronic acid in postmenopause vaginal atrophy: a systematic review. J Sex Med 2021; 18 (01) 156-66
    CrossrefPubMedSearch in Google Scholar
  • 10 Baber RJ, Panay N, Fenton A. IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016; 19 (02) 109-50
    CrossrefPubMedSearch in Google Scholar
  • 11 Donders GG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother 2019; 20 (07) 821-35
    CrossrefPubMedSearch in Google Scholar
  • 12 Nachtigall L, Lang E, Gut R, Utian W, Archer DF, Simon J. An ultra-low dose (10μg) estradiol vaginal tablet improves signs and symptoms associated with vaginal atrophy. Fertil Steril 2008; 90 Suppl: S250
    CrossrefPubMedSearch in Google Scholar
  • 13 Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. VAG-1748 trial investigators. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric 2010; 13 (03) 228-37
    CrossrefPubMedSearch in Google Scholar
  • 14 Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010; 116 (04) 876-83
    CrossrefPubMedSearch in Google Scholar
  • 15 Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric 2010; 13 (03) 219-27
    CrossrefPubMedSearch in Google Scholar
  • 16 Pompei LM, Fernandes CE, Melo NR. Promestrieno no tratamento da atrofia vulvovaginal: revisão sistemática. Femina 2010; 38 (07) 359-65
    PubMedSearch in Google Scholar
  • 17 Sun AJ, Lin SQ, Jing LH, Wang ZY, Ye JL, Zhang Y. [Safety of promestriene capsule used in postmenopausal atrophic vaginitis]. Zhonghua Fu Chan Ke Za Zhi 2009; 44 (08) 593-6 . Chinese
    PubMedSearch in Google Scholar
  • 18 Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P. et al. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?. Anticancer Drugs 2013; 24 (10) 989-98
    CrossrefPubMedSearch in Google Scholar
  • 19 Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause 2019; 26 (04) 431-53
    CrossrefPubMedSearch in Google Scholar
  • 20 Wańczyk-Baszak J, Woźniak S, Milejski B, Paszkowski T. Genitourinary syndrome of menopause treatment using lasers and temperature-controlled radiofrequency. Prz Menopauzalny 2018; 17 (04) 180-4
    CrossrefPubMedSearch in Google Scholar
  • 21 Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A. et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med 2017; 49 (02) 137-59
    CrossrefPubMedSearch in Google Scholar
  • 22 Sarmento AC, Lírio JF, Medeiros KS, Marconi C, Costa AP, Crispim JC. et al. Physical methods for the treatment of genitourinary syndrome of menopause: a systematic review. Int J Gynaecol Obstet 2021; 153 (02) 200-19
    CrossrefPubMedSearch in Google Scholar
  • 23 Knight C, Logan V, Fenlon D. A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors. Ecancermedicalscience 2019; 13: 988
    CrossrefPubMedSearch in Google Scholar
  • 24 Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV. et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014; 124 (06) 1147-56
    CrossrefPubMedSearch in Google Scholar
  • 25 Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012; 10: CD001405
    CrossrefPubMedSearch in Google Scholar
  • 26 Bachmann G, Santen RJ. Genitourinary syndrome of menopause (vulvovaginal atrophy): treatment [Internet]. 2021 [cited 2021 Oct 30]. Available from: https://www.uptodate.com/contents/genitourinary-syndrome-of-menopause-vulvovaginal-atrophy-treatment
    PubMedSearch in Google Scholar
  • 27 Vesna A, Neli B. Benefit and safety of 28-day transdermal estrogen regimen during vaginal hysterectomy (a controlled trial). Maturitas 2006; 53 (03) 282-98
    CrossrefPubMedSearch in Google Scholar
  • 28 ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016; 127 (03) e93-6
    CrossrefPubMedSearch in Google Scholar
  • 29 Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 2018; 25 (06) 596-608
    CrossrefPubMedSearch in Google Scholar
  • 30 American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice. Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer [Internet]. 2016 (Reaffirmed 2020) [cited 2021 Oct 30]. Available from: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2016/03/the-use-of-vaginal-estrogen-in-women-with-a-history-of-estrogen-dependent-breast-cancer
    PubMedSearch in Google Scholar